Cosentyx (secukinumab) is a biologic drug used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While the drug has been shown to be effective in treating these conditions, there have been some safety concerns associated with its use.

According to Drug Patent Watch [1], the most recent safety concern related to Cosentyx is the potential risk of developing inflammatory bowel disease (IBD). In 2020, the U.S. Food and Drug Administration (FDA) issued a safety communication warning of the possible link between Cosentyx and IBD. The FDA advised healthcare professionals to monitor patients for symptoms of IBD, such as diarrhea, rectal bleeding, and abdominal pain, and to discontinue Cosentyx if IBD is suspected.

A study published in the Journal of Clinical Medicine [2] also reported on the safety of Cosentyx in treating psoriasis. The study found that while the drug was generally well-tolerated, there were some adverse events reported, including infections, injection site reactions, and gastrointestinal disorders. However, the study did not specifically address the potential risk of developing IBD.

Another study published in the Journal of Dermatological Treatment [3] evaluated the safety and efficacy of Cosentyx in treating psoriasis in a real-world setting. The study found that while the drug was effective in treating psoriasis, there were some adverse events reported, including infections, injection site reactions, and gastrointestinal disorders. However, the study did not specifically address the potential risk of developing IBD.

In summary, the most recent safety concern related to Cosentyx is the potential risk of developing inflammatory bowel disease. Healthcare professionals are advised to monitor patients for symptoms of IBD and to discontinue Cosentyx if IBD is suspected. While Cosentyx has been shown to be generally well-tolerated, there have been some adverse events reported, including infections, injection site reactions, and gastrointestinal disorders.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214234/
[3] https://pubmed.ncbi.nlm.nih.gov/35754494/